Director Richard Stark filed a Form 4 with the SEC on November 20, 2026, disclosing the acquisition of stock options in RenovoRx, Inc. (NASDAQ:RNXT) on November 18, 2026.
Key Highlights
- Option grant: Richard Stark, a director of RenovoRx, Inc., acquired 128,824 stock options (right to buy) on November 18, 2026.
- Exercise price: The options carry an exercise price of $1.12 per share.
- Expiration date: The options expire on November 17, 2036.
- Vesting schedule: The options vest in 36 equal monthly installments beginning December 18, 2026, subject to the reporting person's continued service.
- Change-in-control provision: The options vest in full upon a change in control of the issuer, according to the filing.
- Post-transaction holdings: Following the transaction, Stark beneficially owns 128,824 derivative securities directly, as reported in the filing.
- Price paid: The price of the derivative security at acquisition was reported as $0.
RenovoRx Director Richard Stark Granted 128,824 Stock Options in November 2026
According to a Form 4 filed with the U.S. Securities and Exchange Commission on November 20, 2026, Richard Stark, a director of RenovoRx, Inc. (NASDAQ:RNXT), was granted 128,824 stock options on November 18, 2026. The options, which are classified as a right to buy common stock, carry an exercise price of $1.12 and are set to expire on November 17, 2036.
The filing discloses that the options were acquired at a price of $0 and are structured to vest in 36 equal monthly installments on the 18th day of each month, beginning December 18, 2026. Vesting is subject to the reporting person's continued service with the issuer. The filing further states that the options "vest in full upon a change in control of the Issuer." The transaction is coded "A," indicating an acquisition.
Following the reported transaction, Stark's total beneficial ownership of derivative securities stands at 128,824 options, held directly. The filing was signed by Richard Stark and dated November 20, 2026. No non-derivative securities transactions were reported in this filing.
What Was Disclosed
Richard Stark, a director at RenovoRx, Inc., disclosed the acquisition of 128,824 stock options at an exercise price of $1.12, expiring November 17, 2036, and vesting over 36 monthly installments beginning December 18, 2026.




Please wait processing your request...